Success Metrics

Clinical Success Rate
66.7%

Based on 8 completed trials

Completion Rate
67%(8/12)
Active Trials
5(25%)
Results Posted
75%(6 trials)
Terminated
4(20%)

Phase Distribution

Ph phase_2
4
20%
Ph phase_1
6
30%
Ph not_applicable
7
35%
Ph phase_3
2
10%

Phase Distribution

6

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
6(31.6%)
Phase 2Efficacy & side effects
4(21.1%)
Phase 3Large-scale testing
2(10.5%)
N/ANon-phased studies
7(36.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

61.5%

8 of 13 finished

Non-Completion Rate

38.5%

5 ended early

Currently Active

5

trials recruiting

Total Trials

20

all time

Status Distribution
Active(6)
Completed(8)
Terminated(5)
Other(1)

Detailed Status

Completed8
Terminated4
Recruiting3
Active, not recruiting2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
5
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (31.6%)
Phase 24 (21.1%)
Phase 32 (10.5%)
N/A7 (36.8%)

Trials by Status

recruiting315%
unknown15%
terminated420%
completed840%
active_not_recruiting210%
withdrawn15%
not_yet_recruiting15%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT03775330

Radiosurgery With or Without Whole Brain Radiation for Multiple Metastases

Active Not Recruiting
NCT03483012Phase 2

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Completed
NCT03550391Phase 3

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Recruiting
NCT06741085Phase 2

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Recruiting
NCT04923542Phase 1

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Recruiting
NCT04474353Phase 1

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Completed
NCT06132945Phase 1

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Active Not Recruiting
NCT01703507Phase 1

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Completed
NCT06047951Not Applicable

Brain Low-risk Aneurysm Stereotactic Radiosurgical Trial

Not Yet Recruiting
NCT03497767Phase 2

A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

Completed
NCT01345539Phase 2

Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

Terminated
NCT01345552Not Applicable

Radiosurgery for Patients Recurrent Oligometastatic Disease

Completed
NCT03488472Not Applicable

Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain

Terminated
NCT03303365Not Applicable

Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence

Completed
NCT01120639Phase 1

Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

Completed
NCT01821443Not Applicable

A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)

Terminated
NCT01731704Not Applicable

Neurocognitive Outcomes In Patients Treated With Radiotherapy For Five Or More Brain Metastases

Withdrawn
NCT01950195Phase 1

SRS (Stereotactic Radiosurgery) Plus Ipilimumab

Terminated
NCT01017250Not Applicable

Radiosurgery and Avastin for Recurrent Malignant Gliomas

Completed
NCT01130766Phase 3

Asymptomatic Brain Metastasis in Non-small Cell Lung Cancer (NSCLC)

Unknown

All 20 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
20